The trial is taking place at:
Q

Quest Clinical Research | San Francisco, CA

Veeva-enabled site

An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study

C

CytoDyn

Status and phase

Active, not recruiting
Phase 3
Phase 2

Conditions

HIV-1-infection

Treatments

Drug: PRO 140 700
Drug: PRO 140 350
Drug: PRO 140 525

Study type

Interventional

Funder types

Industry

Identifiers

NCT05271370
PRO 140_CD03 Extension

Details and patient eligibility

About

This study is a Phase 2b/3 multi-center extension study designed to evaluate the long term antiviral activity, safety, and tolerability of the strategy of continuing PRO 140 350mg, 525mg, or 700mg SC monotherapy to maintain viral suppression after initial 48 weeks in virologically suppressed subjects. Consenting subjects will continue weekly PRO 140 350mg, 525mg, or 700mg monotherapy during the Treatment Extension Phase with the one week overlap of existing retroviral regimen and PRO 140 350mg, 525mg, or 700 mg at the end of the treatment in subjects who do not experience virologic failure.

Full description

The objective is to assess the long-term safety of using PRO 140 350mg, 525mg, or 700mg SC as single-agent maintenance therapy for the chronic suppression of CCR5-tropic HIV-1 infection.

Enrollment

56 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subjects who have completed 48 weeks of treatment in PRO140_CD03 study.
  • Last known Plasma HIV-1 RNA < 50 copies/mL within PRO140_CD03 study.
  • Both male and female patients and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception (e.g., barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized). Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug.
  • Willing and able to participate in all aspects of the study, including use of SC medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent.

Exclusion criteria

  • Not currently enrolled in PRO140_CD03 study.
  • Any active infection or malignancy requiring acute therapy (with the exception of local cutaneous Kaposi's sarcoma).
  • Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study.
  • Subjects weighing < 35kg.
  • History of anaphylaxis to any oral or parenteral drugs.

History of Bleeding Disorder or patients on anti-coagulant therapy (except aspirin).

Note: Subjects with well-controlled bleeding disorder while on stable anti-coagulant therapy dose with documented stable INRs can be enrolled as per discretion of the Investigator.

Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

56 participants in 3 patient groups

PRO 140 350 mg
Experimental group
Description:
PRO 140 350mg weekly SQ injection.
Treatment:
Drug: PRO 140 350
PRO 140 525 mg
Experimental group
Description:
PRO 140 525mg weekly SQ injection.
Treatment:
Drug: PRO 140 525
PRO 140 700 mg
Experimental group
Description:
PRO 140 700mg weekly SQ injection.
Treatment:
Drug: PRO 140 700

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems